Monte S Buchsbaum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7066755/publications.pdf

Version: 2024-02-01

57 3,196 31 53 g-index

59 59 59 59 3944

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	Four-modality imaging of unmedicated subjects with schizophrenia: 18F-fluorodeoxyglucose and 18F-fallypride PET, diffusion tensor imaging, and MRI. Psychiatry Research - Neuroimaging, 2022, 320, 111428.	0.9	1
2	Neurocognitive profile of adolescents with early-onset schizophrenia and their unaffected siblings. World Journal of Biological Psychiatry, 2022, 23, 677-688.	1.3	4
3	Fluorodeoxyglucose positron emission tomography scans in patients with alcohol use disorder. Alcoholism: Clinical and Experimental Research, 2022, 46, 994-1010.	1.4	4
4	Neural Correlates of Autobiographical Memory: Evidence From a Positron Emission Tomography Study in Patients With Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Psychiatry, 2021, 12, 730713.	1.3	1
5	Reading abilities and dopamine D2/D3 receptor availability: An inverted U-shaped association in subjects with schizophrenia. Brain and Language, 2021, 223, 105046.	0.8	4
6	Dopamine receptor density and white mater integrity: 18F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects. Brain Imaging and Behavior, 2020, 14, 736-752.	1.1	11
7	Positive association between cerebral grey matter metabolism and dopamine D ₂ /D ₃ receptor availability in healthy and schizophrenia subjects: An ¹⁸ F-fallypride positron emission tomography study. World lournal of Biological Psychiatry, 2020, 21, 368-382.	1.3	14
8	Relationship between white matter glucose metabolism and fractional anisotropy in healthy and schizophrenia subjects. Psychiatry Research - Neuroimaging, 2020, 299, 111060.	0.9	3
9	Forty years of editorship of psychiatry research. Psychiatry Research, 2019, 277, 4-9.	1.7	1
10	Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. Brain Imaging and Behavior, 2018, 12, 532-546.	1.1	43
11	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naÃ-ve patients with schizophrenia. Schizophrenia Research, 2018, 192, 442-456.	1.1	14
12	Bimagrumab improves body composition and insulin sensitivity in insulinâ€resistant individuals. Diabetes, Obesity and Metabolism, 2018, 20, 94-102.	2.2	59
13	Increased white matter metabolic rates in autism spectrum disorder and schizophrenia. Brain Imaging and Behavior, 2018, 12, 1290-1305.	1.1	19
14	Multimodal canonical correlation reveals converging neural circuitry across trauma-related disorders of affect and cognition. Neurobiology of Stress, 2018, 9, 241-250.	1.9	15
15	Diametrical relationship between gray and white matter volumes in autism spectrum disorder and schizophrenia. Brain Imaging and Behavior, 2017, 11, 1823-1835.	1.1	22
16	Faking bad: The neural correlates of feigning memory impairment Neuropsychology, 2016, 30, 377-384.	1.0	6
17	FDG-PET scans in patients with Kraepelinian and non-Kraepelinian schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 481-494.	1.8	13
18	Corpus callosum size and diffusion tensor anisotropy in adolescents and adults with schizophrenia. Psychiatry Research - Neuroimaging, 2015, 231, 244-251.	0.9	43

#	Article	IF	CITATIONS
19	Neural correlates of malingering in mild traumatic brain injury: A positron emission tomography study. Psychiatry Research - Neuroimaging, 2015, 233, 367-372.	0.9	10
20	Clusters of Low ¹⁸ F-Fluorodeoxyglucose Uptake Voxels in Combat Veterans with Traumatic Brain Injury and Post-Traumatic Stress Disorder. Journal of Neurotrauma, 2015, 32, 1736-1750.	1.7	33
21	Serotonin transporter binding after recovery from bulimia nervosa. International Journal of Eating Disorders, 2012, 45, 345-352.	2.1	21
22	Evidence, Evidence-Based Medicine, and Evidence Utility in Psychiatry and Electrophysiology. Clinical EEG and Neuroscience, 2009, 40, 143-145.	0.9	4
23	FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophrenia Research, 2009, 114, 161-171.	1.1	32
24	Comparison between Voxel-based Morphometry and Volumetric Analysis in Schizophrenia., 2008,,.		1
25	FDG-PET Study in Pathological Gamblers. Neuropsychobiology, 2008, 58, 37-47.	0.9	45
26	Relative Glucose Metabolic Rate Higher in White Matter in Patients With Schizophrenia. American Journal of Psychiatry, 2007, 164, 1072-1081.	4.0	89
27	FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophrenia Research, 2007, 94, 293-305.	1.1	37
28	Diffusion Tensor Imaging in Schizophrenia. Biological Psychiatry, 2006, 60, 1181-1187.	0.7	115
29	D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research, 2006, 85, 232-244.	1.1	128
30	Thalamocortical circuits: fMRI assessment of the pulvinar and medial dorsal nucleus in normal volunteers. Neuroscience Letters, 2006, 404, 282-287.	1.0	51
31	Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. Annals of General Psychiatry, 2006, 5, 19.	1.2	79
32	Positron Emission Tomography Imaging of Risperidone Augmentation in Serotonin Reuptake Inhibitor-Refractory Patients. Neuropsychobiology, 2006, 53, 157-168.	0.9	33
33	Correlations between MRI-assessed volumes of the thalamus and cortical Brodmann's areas in schizophrenia. Schizophrenia Research, 2005, 75, 265-281.	1.1	47
34	Neuropsychological Functioning in First-Break, Never-Medicated Adolescents With Psychosis. Journal of Nervous and Mental Disease, 2004, 192, 615-622.	0.5	70
35	Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophrenia Research, 2003, 64, 53-62.	1.1	91
36	MRI Assessment of Gray and White Matter Distribution in Brodmann's Areas of the Cortex in Patients With Schizophrenia With Good and Poor Outcomes. American Journal of Psychiatry, 2003, 160, 2154-2168.	4.0	106

#	Article	IF	CITATIONS
37	Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate. Schizophrenia Research, 2002, 55, 25-40.	1.1	30
38	Differential metabolic rates in prefrontal and temporal Brodmann areas in schizophrenia and schizotypal personality disorder. Schizophrenia Research, 2002, 54, 141-150.	1.1	109
39	Sleep deprivation as a model experimental antidepressant treatment: Findings from functional brain imaging. Depression and Anxiety, 2001, 14, 37-49.	2.0	101
40	Clinical Neurochemical Implications of Sleep Deprivation's Effects on the Anterior Cingulate of Depressed Responders. Neuropsychopharmacology, 2001, 25, S74-S78.	2.8	51
41	Positron Emission Tomography with Deoxyglucose-F18 Imaging of Sleep. Neuropsychopharmacology, 2001, 25, S50-S56.	2.8	47
42	Magnetic Resonance Imaging of the Thalamic Mediodorsal Nucleus and Pulvinar in Schizophrenia and Schizotypal Personality Disorder. Archives of General Psychiatry, 2001, 58, 133.	13.8	194
43	d,l-fenfluramine Response in Impulsive Personality Disorder Assessed with [18F]fluorodeoxyglucose Positron Emission Tomography. Neuropsychopharmacology, 1999, 20, 413-423.	2.8	257
44	Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology, 1998, 35, 186-198.	1,2	149
45	Automatic MR-PET registration algorithm. International Journal of Imaging Systems and Technology, 1998, 9, 46-50.	2.7	0
46	Language in Dreaming and Regional EEG Alpha Power. Sleep, 1996, 19, 232-235.	0.6	33
47	Localized and Lateralized Cerebral Glucose Metabolism Associated With Eye Movements During REM Sleep and Wakefulness: A Positron Emission Tomography (PET) Study. Sleep, 1995, 18, 570-580.	0.6	221
48	Glucose metabolic rate and progression of illness in Alzheimer's disease. International Journal of Geriatric Psychiatry, 1995, 10, 659-667.	1.3	5
49	Charting the circuits. Nature, 1995, 378, 128-129.	13.7	9
50	Neuroimaging and the aging process in psychiatry. International Review of Psychiatry, 1994, 6, 109-118.	1.4	3
51	Striatal Metabolic Rate and Clinical Response to Neuroleptics in Schizophrenia. Archives of General Psychiatry, 1992, 49, 966.	13.8	174
52	The Effect of Sleep Deprivation on Cerebral Glucose Metabolic Rate in Normal Humans Assessed with Positron Emission Tomography. Sleep, 1991, , .	0.6	67
53	Testing the Swerdlow/Koob model of schizophrena pathophysiology using positron emission tomography. Behavioral and Brain Sciences, 1990, 13, 168-170.	0.4	51
54	Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission Tomography. British Journal of Psychiatry, 1990, 156, 216-227.	1.7	297

#	Article	IF	CITATIONS
55	Brain imaging techniques for diagnosis and drugs against schizophrenia. Drug Development Research, 1986, 9, 53-62.	1.4	O
56	Positron emission tomographic image measurement in schizophrenia and affective disorders. Annals of Neurology, 1984, 15, 157-169.	2.8	123
57	ERPs and Psychopathology Annals of the New York Academy of Sciences, 1984, 425, 523-545.	1.8	6